We are live on ! Find out more
JGUA

John G. Ullman & Associates Portfolio holdings

AUM $824M
1-Year Est. Return 78.19%
This Fund
S&P 500
This Quarter Est. Return
+8.39%
1 Year Est. Return
+78.19%
3 Year Est. Return
+156.18%
5 Year Est. Return
+168.38%
10 Year Est. Return
+388.18%
AUM
$581M
AUM Growth
+$30.4M
Cap. Flow
-$10M
Cap. Flow %
-1.73%
Top 10 Hldgs %
36.14%
Holding
153
New
9
Increased
29
Reduced
79
Closed
11

Top Buys

Rank Stock Value
1
ALB icon
Albemarle
ALB
+$4.84M
2
IBM icon
IBM
IBM
+$2.62M
3
CCK icon
Crown Holdings
CCK
+$2.33M
4
TDC icon
Teradata
TDC
+$2.15M
5
HPQ icon
HP
HPQ
+$2.12M

Sector Composition

Rank Sector Weight
1 Healthcare 26.22%
2 Industrials 24.32%
3 Technology 18.63%
4 Miscellaneous 8.16%
5 Utilities 6.62%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
EMR icon
1
Emerson Electric
EMR
$86.6B
$45.4M 7.81%
594,739
-27,068
-4% -$1.95M
BMY icon
2
Bristol-Myers Squibb
BMY
$136B
$26.6M 4.58%
414,748
-480
-0.1% -$27.5K
GLW icon
3
Corning
GLW
$128B
$25.8M 4.43%
884,776
+35,861
+4% +$1.04M
PFE icon
4
Pfizer
PFE
$159B
$19.1M 3.29%
514,317
+29,084
+6% +$1.04M
XOM icon
5
ExxonMobil
XOM
$644B
$17.9M 3.08%
256,698
-96,727
-27% -$6.69M
INTC icon
6
Intel
INTC
$473B
$17.9M 3.08%
298,613
-5,033
-2% -$282K
NVS icon
7
Novartis
NVS
$292B
$14.7M 2.53%
155,350
-2,775
-2% -$249K
GSK icon
8
GSK
GSK
$102B
$14.7M 2.52%
249,500
-5,740
-2% -$319K
MMM icon
9
3M
MMM
$89.9B
$14.4M 2.48%
97,531
-1,047
-1% -$147K
JNJ icon
10
Johnson & Johnson
JNJ
$646B
$13.6M 2.33%
92,968
-530
-0.6% -$71.9K
OGE icon
11
OGE Energy
OGE
$9.45B
$12.5M 2.14%
280,118
-3,850
-1% -$166K
XRAY icon
12
Dentsply Sirona
XRAY
$2.22B
$12M 2.07%
212,900
-4,050
-2% -$226K
EEMV icon
13
iShares MSCI Emerging Markets Min Vol Factor ETF
EEMV
$3.65B
$11.9M 2.04%
202,114
-5,125
-2% -$297K
FLS icon
14
Flowserve
FLS
$10.2B
$11.6M 1.99%
232,307
-4,190
-2% -$201K
MDU icon
15
MDU Resources
MDU
$4.16B
$11.3M 1.95%
1,001,847
-21,959
-2% -$240K
LGTY
16
DELISTED
Logility Supply Chain Solutions, Inc. Common Stock
LGTY
$11.2M 1.92%
751,256
-19,611
-3% -$308K
LNN icon
17
Lindsay Corp
LNN
$1.16B
$10.6M 1.82%
110,118
-8,030
-7% -$734K
BCE icon
18
BCE
BCE
$21.9B
$10.6M 1.82%
227,751
-2,500
-1% -$120K
MSFT icon
19
Microsoft
MSFT
$3.81T
$9.08M 1.56%
57,587
-12,281
-18% -$1.8M
IBM icon
20
IBM
IBM
$222B
$9.02M 1.55%
70,349
+20,136
+40% +$2.62M
BNS icon
21
Scotiabank
BNS
$113B
$8.86M 1.52%
156,775
-3,725
-2% -$212K
TMO icon
22
Thermo Fisher Scientific
TMO
$230B
$7.7M 1.32%
23,688
-1,169
-5% -$354K
ABT icon
23
Abbott
ABT
$195B
$7.68M 1.32%
88,417
-821
-0.9% -$68.8K
MRK icon
24
Merck
MRK
$366B
$7.46M 1.28%
86,005
-2,096
-2% -$172K
TEL icon
25
TE Connectivity
TEL
$58.7B
$7.45M 1.28%
77,700
-900
-1% -$83.3K

Similar funds

John G. Ullman & Associates's Q4 2019 Portfolio in Review

As of Q4 2019, John G. Ullman & Associates held 153 positions worth $581M, up 5.5% from $551M the previous quarter. Its ten largest holdings account for 36% of the portfolio.

John G. Ullman & Associates's Q4 2019 filing shows 9 new, 29 increased, 79 reduced and 11 closed positions. Its largest new stake was Albemarle: 72,500 shares worth $5.29M. The largest sale was ExxonMobil, an estimated $6.69M.

By sector, the portfolio is most concentrated in Healthcare at 26% of assets, up from 25% a quarter earlier, followed by Industrials and Technology.

  • John G. Ullman & Associates's largest Q4 2019 buy was Albemarle: 72,500 shares worth $5.29M.
  • John G. Ullman & Associates added most to IBM in Q4 2019, an estimated $2.62M increase.
  • John G. Ullman & Associates's biggest Q4 2019 reduction was ExxonMobil, cutting an estimated $6.69M.
  • John G. Ullman & Associates fully exited Arista Networks in Q4 2019, selling an estimated $2.33M.
  • John G. Ullman & Associates's ten largest holdings make up 36% of its $581M portfolio in Q4 2019.
  • John G. Ullman & Associates opened 9 new positions and closed 11 in Q4 2019.
  • John G. Ullman & Associates's portfolio value rose 5.5% quarter-over-quarter to $581M.

Based on John G. Ullman & Associates's 13F filing for Q4 2019, filed 29 Jan 2020.